Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models CANCER DISCOVERY Thomas, D., Majeti, R. 2017; 7 (5): 459–61

View details for DOI 10.1158/2159-8290.CD-17-0270

View details for Web of Science ID 000400269300018